Please use this identifier to cite or link to this item:
Title: A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Authors: Dretzke, J
Edlin, R
Round, J
Connock, M
Hulme, C
Czeczot, J
Fry-Smith, A
McCabe, C
Meads, C
Keywords: Anti-Inflammatory Agents;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antirheumatic Agents;Cost-Benefit Analysis;Crohn Disease;Decision Support Techniques;Models, Economic;Quality-Adjusted Life Years;Treatment Outcome;Tumor Necrosis Factor-alpha
Issue Date: 2011
Publisher: NIHR Health Technology Assessment Programme
Citation: Health Technology Assessment, 15(6), 1 - 244, 2011
Abstract: Crohn's disease (CD) is a severe, lifelong disease characterised by inflammation of the gastrointestinal mucosa. The impact on patients and society is high as ill health can be lifelong and can negatively affect patients' quality of life. Costs to the NHS are high, particularly for patients needing hospitalisation. Conventional treatment pathways are complex. More recently, a group of drugs called tumour necrosis factor (TNF) inhibitors (anti-TNF-α agents) have been evaluated for their effectiveness in CD. One of these, infliximab, is currently recommended by the National Institute for Health and Clinical Excellence (NICE; 2002) for patients with severe, active CD where patients are refractory to or intolerant of conventional treatment.
Description: © 2011 Queen’s Printer and Controller of HMSO
ISSN: 1366-5278
Appears in Collections:Publications
Health Economics Research Group (HERG)

Files in This Item:
File Description SizeFormat 
Fulltext.pdf338.48 kBAdobe PDFView/Open

Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.